Literature DB >> 6571733

Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA).

P Hokland, P Rosenthal, J D Griffin, L M Nadler, J Daley, M Hokland, S F Schlossman, J Ritz.   

Abstract

Fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA) were purified from both fetal liver and fetal bone marrow by immune rosetting with sheep erythrocytes coated with rabbit anti-mouse immunoglobulin and by fluorescence-activated cell sorting. Dual fluorescence techniques disclosed that these cells were heterogenous with respect to the expression of a series of differentiation and activation antigens defined by monoclonal antibodies. Thus, whereas all CALLA+ cells were Ia+ and expressed two activation antigens, J2 and T10, only 30-50% expressed B1 antigen. Furthermore, using methanol-fixed cells, it could be shown that approximately 20% contained intracytoplasmic mu chains (cyto-mu) and that approximately 15% were positive for the terminal transferase enzyme (TdT) marker. The CALLA+ fetal cells thus closely resemble the childhood acute lymphoblastic leukemia cell with respect to surface marker phenotype. A population of CALLA- cells devoid of mature erythroid and myeloid surface markers was found to contain higher numbers of TdT+ cells but lower numbers of cyto-mu, B1, and Ia+ cells than the CALLA+ subset. In vitro analysis of normal, purified CALLA+ cells demonstrated that incubation at 37 degrees C with J5 monoclonal antibody specific for CALLA resulted in the specific modulation of surface antigen. Similar results have previously been obtained with CALLA+ tumor cells. Although phenotypic analysis of CALLA+ cells suggests that these cells are relatively immature lymphoid cells, CALLA+ cells do not appear to contain either myeloid precursor cells (CFU-G/M) or the earliest lymphoid stem cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571733      PMCID: PMC2186888          DOI: 10.1084/jem.157.1.114

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients.

Authors:  J D Griffin; R P Beveridge; S F Schlossman
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

2.  Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.

Authors:  J Ritz; L M Nadler; A K Bhan; J Notis-McConarty; J M Pesando; S F Schlossman
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

3.  Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.

Authors:  L M Nadler; J Ritz; M P Bates; E K Park; K C Anderson; S E Sallan; S F Schlossman
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

4.  Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement.

Authors:  J Ritz; S E Sallan; R C Bast; J M Lipton; L A Clavell; M Feeney; T Hercend; D G Nathan; S F Schlossman
Journal:  Lancet       Date:  1982-07-10       Impact factor: 79.321

5.  Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.

Authors:  J Ritz; J M Pesando; S E Sallan; L A Clavell; J Notis-McConarty; P Rosenthal; S F Schlossman
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

6.  Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.

Authors:  L A Clavell; J M Lipton; R C Bast; M Kudisch; J Pesando; S F Scholssman; J Ritz
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

7.  Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man.

Authors:  L M Nadler; P Stashenko; R Hardy; J M Pesando; E J Yunis; S F Schlossman
Journal:  Hum Immunol       Date:  1981-02       Impact factor: 2.850

8.  Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody.

Authors:  J M Pesando; J Ritz; H Lazarus; K J Tomaselli; S F Schlossman
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

9.  Antigens on human monocytes identified by monoclonal antibodies.

Authors:  R F Todd; L M Nadler; S F Schlossman
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

10.  Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes.

Authors:  D T Fearon; I Kaneko; G G Thomson
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

View more
  12 in total

1.  Haemopoiesis in human fetal and embryonic liver. Immunohistochemical determination in B5-fixed paraffin-embedded tissues.

Authors:  W Timens; W A Kamps; T Rozeboom-Uiterwijk; S Poppema
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization.

Authors:  D Delia; G Cattoretti; A Bonati; S Villa; F De Braud; M Buscaglia
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

3.  Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.

Authors:  M A Shipp; N E Richardson; P H Sayre; N R Brown; E L Masteller; L K Clayton; J Ritz; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

4.  Immunobiologic differences between normal and leukemic human B-cell precursors.

Authors:  F M Uckun; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.

Authors:  S Y Xiao; H L Wang; J Hart; D Fleming; M R Beard
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

6.  B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.

Authors:  L M Nadler; S J Korsmeyer; K C Anderson; A W Boyd; B Slaughenhoupt; E Park; J Jensen; F Coral; R J Mayer; S E Sallan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

7.  Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.

Authors:  G Salles; H R Rodewald; B S Chin; E L Reinherz; M A Shipp
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.

Authors:  C V Jongeneel; E J Quackenbush; P Ronco; P Verroust; S Carrel; M Letarte
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

9.  Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.

Authors:  M A Shipp; J Vijayaraghavan; E V Schmidt; E L Masteller; L D'Adamio; L B Hersh; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

10.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.